Drug Profile


Alternative Names: 823296; GW 823296; GW823296X

Latest Information Update: 14 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator GlaxoSmithKline
  • Developer NeRRe Therapeutics
  • Class Antidepressants; Anxiolytics
  • Mechanism of Action Neurokinin 1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Cough; Pruritus
  • Discontinued Anxiety disorders; Major depressive disorder; Post-traumatic stress disorders

Most Recent Events

  • 10 May 2017 Phase-II clinical trials in Cough in USA (PO) (NCT02993822)
  • 20 Dec 2016 Nerre Therapeutics plans a phase II trial for Cough in USA (NCT02993822)
  • 19 Dec 2015 NeRRe Therapeutics terminates a phase II trial in Pruritus in Italy and the United Kingdom (EudraCT2013-002763-25)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top